Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Quick Links

Call customer care

Gloved hand administering Obsidio Conformable Embolic.

Obsidio™ Conformable Embolic

Data

Clinical studies

Explore studies evaluating safety and performance outcomes of Obsidio Embolic.

Obsidio Embolic Limited Market Evaluation (LME) report

Background – Obsidio received 510(k) clearance in July 2022 and Boston Scientific acquired Obsidio (formerly GEM/Gel Embolic Material) from Obsidio, Inc. in August 2022. Boston Scientific chose to launch Obsidio Embolic in the US through a limited market evaluation (LME) to obtain early user experience prior to moving into a full commercial launch.

Methods – 27 sites in the US were chosen for the LME. Post completion of each case, the commercial representatives were tasked with completion of a case report survey.

Technical Success – Technical success for a Obsidio Embolic case was defined as successful embolization of the target vasculature. In the LME, Obsidio Embolic was able to achieve embolization target in all cases and had a success rate of 100% (131/131 cases).

Filename
obsidio-lme-data-sheet.pdf
Size
523 KB
Format
application/pdf
Download LME report

OCCLUDE Registry Overview

Objective – Assess effectiveness and safety outcomes of patients who undergo embolization with Obsidio Conformable Embolic.

Planned number of site/subjects – Up to 125 patients, 23 sites in US.

Follow-up schedule – Pre-procedure, Index Procedure, discharge, 7-Day and 1-Month follow up visit (phone or in-office).

Interim Analysis (IA) – IA planned after 60 patients have completed follow up.

Filename
obsidio-embolic-occlude-registry-fact-sheet.pdf
Size
559 KB
Format
application/pdf
Download OCCLUDE fact sheet

Obsidio first-in-human clinical study: evaluation of Obsidio Embolic safety and performance

Overview – A single-center study* sought to evaluate the safety and performance of Obsidio Conformable Embolic (OCE) in patients requiring vascular embolization for hypervascular renal tumors.

Objectives – The study sought to demonstrate that Obsidio Embolic could be delivered safely, occludes the artery where deposited without migration, and does not lead to a change in standard blood tests.

Results – Obsidio Embolic achieved the absence of flow in the blood vessels of tumors, with embolization demonstrated to be durable without migration at Day 7.

* Obsidio Conformable Embolic performance testing

Filename
obsidio-human-feasibility-study1.pdf
Size
1013 KB
Format
application/pdf
Download Obsidio paper


Single-center experiences

Procedures across multiple studies support broad clinical utility, showing consistently high technical success and reliable performance across a wide range of indications.

MD Anderson – A Single-Center Experience with a Shear-Thinning Conformable Embolic 

Recently published in JVIR, the retrospective study evaluated outcomes after embolization using Obsidio Embolic and demonstrated a treatment effectiveness rate of 100%.

Filename
obsidio-embolic-md-anderson-publication-summary.pdf
Size
513 KB
Format
application/pdf
Download publication summary

University of Chicago – A Novel Conformable Embolic for Selective Transarterial Embolization of Acute Hemorrhages: A Technical Note

A single center’s early experience in using Obsidio Embolic for treating acute intra-abdominal hemorrhage in three patients highlights safety, technique, and effectiveness. In all cases, Obsidio Embolic completely occluded the target vessel.

Filename
obsidio-embolic-uchicago-publication-summary.pdf
Size
1 MB
Format
application/pdf
Download publication summary

Rutgers University – A Single Institution Experience with a Shear-Thinning Conformable Embolic for Endovascular Embolization

A 21-patient study assessing the safety and feasibility of Obsidio Embolic for treatment in peripheral hemorrhage, preoperative tumors, and precryoablation tumors reported 100% technical success.

Filename
obsidio-embolic-rutgers-publication-summary.pdf
Size
508 KB
Format
application/pdf
Download publication summary

University of North Carolina – Early Experience Using Tantalum-Loaded Nanocomposite Hydrogel Conformable Embolic for Upper Gastrointestinal Bleeding: Open-Sandwich Technique

This study reported results from 10 consecutive gastroduodenal artery embolization (GDA) procedures performed using Obsidio Embolic and demonstrated 100% technical success.

Filename
obsidio-embolic-unc-publication-summary.pdf
Size
504 KB
Format
application/pdf
Download publication summary
document icon with purple arrow pointing up.

Submit your Obsidio case